Arthi Sridhar
@ASridharMD
Followers
942
Following
2K
Media
50
Statuses
1K
Thoracic Oncologist @UTSWHemeOnc | Training @MayoCancerCare, @McGovernHemeOnc| #LCSM #globaloncology #patienteducation #meded| @ASCOTECAG | Tweets are mine
Joined January 2017
🚨🎙️Just Published: Our piece on Shared Decision Making (SDM) for Personalized #LungCancer Care. In this article, we highlight the scope and need for Purposeful SDM: ➡️ SDM captures the collaborative conversations between patients and clinicians—whether it’s navigating tough
1
3
15
Excited to see our chapter on molecular and targeted therapies for cancer in this issue of Thoracic Surgery Clinics! Grateful for the opportunity to contribute @Florez_Lab @utswcancer @UTSWHemeOnc
Proud to see our chapter included in this edition of Precision Medicine in Thoracic Surgery. Appreciative of the rigorous collaboration that made this contribution possible.
0
2
5
A comprehensive list of articles written by our very own @ASCOTECAG members summarising key panel talks for trainees and early career oncologists everywhere! Great work led by our very own @NazliDizman
💫Missed @ASCOTECAG #Trainee & Early Career #Oncologist Lounge sessions #ASCO25? We turned key panels into editorials so everyone can easily access expert professional development insights! 🔶Series overview https://t.co/vpSdbN2d0j by @NazliDizman
@ASCO #MedEd #ASCO26 @ASCOPres
0
2
6
💫First Job Search Tips for Hematology-Oncology Fellows: An excellent guide by @Noha_Soror and @ASridharMD on the wisdom pearls shared at @ASCO25 by @ASridharMD @AnaVManana @quirogad 🔶 https://t.co/YtO3GAFOv8
#ASCO26 #ASCO25 @ASCO #MedEd #OncTwitter
1
4
9
New in @JCO_ASCO CHRYSALIS-2 Cohort C shows amivantamab + lazertinib delivers meaningful and durable activity in atypical EGFR-mutated NSCLC (G719X, L861Q, S768I). ORR 52% overall, 57% in 1L, and IMPRESSIVE mPFS up to 19.5 months with no new safety signals. A real step forward
ascopubs.org
PURPOSEFor patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment...
2
25
59
Tune in today for our segment on Good Morning America about Young Lung Cancer - 8:30 am EST. @YoungLungCancer @DanaFarberNews @DFEGFRcenter @Florez_Lab
@GMA @OncoAlert
2
15
52
Dr. Sridhar’s research brings clarity and compassion to a topic many experience but few discuss: burnout for young faculty. @ASridharMD @IASLC
1
3
11
This morning we presented some results from the BREATHE study ➡️35% of respondants experienced severe burnout by MBI ➡️ close to 50% had self reported symptoms of burnout ➡️ Over 80% still had a high sense of personal accomplishment @lungoncdoc @drshieldsmd @ipreeshagul
So proud of @ASridharMD sharing results from our BREATHE study: the first to characterize burnout in early-career thoracic oncologists. 🔥 >1 in 3 early-career oncologists affected 💡 Marriage, sleep & family responsibility appear to be protective @IASLC #NACLC25
0
3
14
High rates of burnout among early-career thoracic oncology faculty were just presented at #NACLC2025—this isn’t a personal failure, it’s a systemic problem. Long hours, emotional load, and constant pressure are taking a toll. @ASridharMD @AnaVManana @IASLC
2
15
37
Beautifully organized ECR session featuring national survey data from @ASridharMD, with an insightful table discussion led by @christinemphmd. Much appreciated! @WeillCornell @WCM_MeyerCancer @IASLC #NACLC25
0
2
8
Starting now ⭐️ Fueling the Future: A Networking Breakfast for Trainees and Early Professionals ⭐️ at #NACLC25 with Drs. @HwakeleeMD @christinemphmd @ASridharMD @kamarroneMD Jennifer Li and Seungjun Kim
0
8
21
Join us for the early career and trainee networking breakfast at @IASLC #NACLC25 tomorrow morning 12/6! @HemOncFellows
#lcsm
https://t.co/iADodK8Kya
naclc-iaslc.org
0
4
8
At nearly 100, Dr K. Laxmi Bai donated her life savings ₹3.4 crore to AIIMS Bhubaneswar to build a gynae-oncology unit for women fighting cancer in #Odisha. Born in 1926, she was among the first MBBS batch at SCB Cuttack, later earning her MD and even an MPH from Johns
24
169
962
Safety & efficacy of olomorasib + pembrolizumab in KRAS G12C NSCLC @JTOonline. RR 57%: 74% as first-line and 90% as first line in PD-L1 high. G3+ TRAEs in 33% with 20% dose reductions of olomorasib and only 6.5% required discontinuation of both for TRAE. https://t.co/0uLyg8Up0r
jto.org
Immunotherapy-based regimens are the standard first-line treatment for KRAS G12C-mutant NSCLC, but outcomes remain suboptimal. Prior attempts to combine KRAS G12C inhibitors with immunotherapy have...
1
24
66
Sevabertinib (oral TKI) now @US_FDA ✅ based off #SOHO01 in previously treated mNSCLC w/ HER2+: - ORR 60% w/ disease control in 84% - AEs includied diarrheaby but no pneumonitis - We now have TDxD, Zongertinib, and Sevabertinib #OncTwitter #MedTwitter @herbloong @LeXiuning
3
17
32
Exciting new press release data for #ALKOVE Ph1/2 trial for #neladalkib for @ALKPositiveinc #lungcancer patients 🎯N=253 ALK TKI–pretreated (most post-lorlatinib) 🎯ORR 31%; DoR 64% (12 mo) / 53% (18 mo) ; meaningful Intracranial responses ⬇️ Discontinuation 5%; dose reduction
Today, we shared positive topline pivotal results for our investigational candidate, neladalkib, in TKI pre-treated patients with advanced ALK+ NSCLC from our global ALKOVE-1 Phase 1/2 clinical trial. Learn more here: https://t.co/GokuPtLLzz
0
4
7
During #LungCancer Awareness Month, I had the pleasure of participating in @UTSWHemeOnc Updates in Oncology. We debated frontline therapies in #EGFR mutated lung cancer. Had a blast with friend and colleague- @MVonitzstein. @SawsanRashdanMD
0
3
21
Dr @SheenaBhallaMD gave an outstanding talk on 2025 Thoracic Oncology Updates. @utswcancer @UTSWMedCenter
0
2
4
🚨Join our @ASCO #IMG CoP Webinar on Visa Options! 🗓️Nov 10, 5-6 pm CT We’ll cover: • Visa types, eligibility & timelines • Waiver options • Permanent residence pathways • Change-of-status info 🔗 https://t.co/Nv8P4hPrym
@ASCOTECAG @HemOncFellows @OncBrothers #MedEd #Match2026
1
25
43